Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gahrton, G; Iacobelli, S; Björkstrand, B; Hegenbart, U; Gruber, A; Greinix, H; Volin, L; Narni, F; Carella, AM; Beksac, M; Bosi, A; Milone, G; Corradini, P; Schönland, S; Friberg, K; van Biezen, A; Goldschmidt, H; de Witte, T; Morris, C; Niederwieser, D; Garderet, L; Kröger, N; EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee.
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Blood. 2013; 121(25): 5055-5063.
Doi: 10.1182/blood-2012-11-469452
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of the European Group for Blood and Marrow Transplantation Non-Myeloablative Allogeneic stem cell transplantation in Multiple Myeloma (NMAM)2000 study that prospectively compares tandem autologous/reduced intensity conditioning allogeneic transplantation (auto/RICallo) to autologous transplantation alone (auto). There are 357 myeloma patients up to age 69 years enrolled. Patients with an HLA-identical sibling were allocated to auto/RICallo (n = 108) and those without to auto alone (n = 249). At 96 months progression-free survival (PFS) and overall survival (OS) were 22% and 49% vs 12% (P = .027) and 36% (P = .030) with auto/RICallo and auto respectively. The corresponding relapse/progression rate (RL) was 60% vs 82% (P = .0002). Non-relapse mortality at 36 months was 13% vs 3% (P = .0004). In patients with the del(13) abnormality corresponding PFS and OS were 21% and 47% vs 5% (P = .026), and 31% (P = .154). Long-term outcome in patients with multiple myeloma was better with auto/RICallo as compared with auto only and the auto/RICallo approach seemed to overcome the poor prognostic impact of del(13) observed after autologous transplantation. Follow up longer than 5 years is necessary for correct interpretation of the value of auto/RICallo in multiple myeloma.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Disease-Free Survival -
- Female -
- Follow-Up Studies -
- Hematopoietic Stem Cell Transplantation - methods Hematopoietic Stem Cell Transplantation - mortality
- Humans -
- Male -
- Middle Aged -
- Multiple Myeloma - mortality Multiple Myeloma - surgery
- Time -
- Transplantation Conditioning - methods
- Transplantation, Autologous - methods
- Transplantation, Homologous - methods
- Treatment Outcome -